Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some ofthe highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies. © McCubrey et al.
|Titolo:||Advances in targeting signal transduction pathways.|
|Data di pubblicazione:||2012|
|Citazione:||Advances in targeting signal transduction pathways. / McCubrey JA; Steelman LS; Chappell WH; Sun L; Davis NM; Abrams SL; Franklin RA; Cocco L; Evangelisti C; Chiarini F; Martelli AM; Libra M; Candido S; Ligresti G; Malaponte G; Mazzarino MC; Fagone P; Donia M; Nicoletti F; Polesel J; Talamini R; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Dulinska-Litewka J; Laidler P; D'Assoro AB; Drobot L; Umezawa K; Montalto G; Cervello M; Demidenko ZN. - In: ONCOTARGET. - ISSN 1949-2553. - 3:12(2012), pp. 1505-1521.|
|Appare nelle tipologie:||1.1 Articolo in rivista|